Date: October 30, 2021 @ 8:30 am – @ 4:30 pm
Location: Virtual Zoom Conference
Less than 10 days away from the CABS 2021 BIOPACIFIC CONFERENCE! The conference will be held on Oct 30, 2021 via Zoom. It features 2 keynote speeches by Nobel Laureate, Dr. Randy Schekman, and Professor/Entrepreneur, Dr. Greg Verdine, as well as 19 podium presentations and 2 panel discussions.
Click Here to Register on Zoom Conference
https://cabs-2021-biopacific-conference.eventbrite.com
CABS is one of the largest non-profit biopharmaceutical professional organizations in San Francisco Bay Area. We are very pleased to host our 22nd annual conference virtually on Oct 30, 2021. This year's conference theme is “Passion for Better Medicine - Leading Biotechnology and Innovation”. We are expecting to attract more than 600 attendees globally, from the life science and Biopharmaceutical industries. The conference features 2 keynote speeches, 19 podium presentations and 2 panel discussions. The covered topics include: cutting-edge science and technology including gene therapy, cell therapy and next generation cancer immunotherapy; patent and legal considerations in life sciences; latest developments in biopharmaceutical policies and regulations; cross-border investment trend and M&A deals in the life sciences field during the COVID-19 pandemic.
Highlights of The 2021 BioPacific Conference:
- Targeted Cas9/gRNA delivery for potential in vivo genome editing
- New technology to develop drugs for previously undruggable targets
- Winners of the 2021 CABS K. Fong Award in Life Sciences
- Machine learning for drug development
- Cancer immunotherapy in the post checkpoint Inhibitor era
- New technologies in cell therapy
- A first-in-class small molecular drug developed for HIV treatmentRegulatory considerations for early cancer detection and precision oncology
- Status review of COVID-For learn more about the speakers and panelists19 pandemic
- Investment trend and deal discussions in biopharmaceutical industries
- IP and patent highlights in recent years
To learn more about the conference agenda, the speakers and panelists, see below attachments:
|
Morning Session |
|
|
8:30 AM – 8:50 AM |
Breakout Room Networking |
|
8:50 AM – 8:55 AM |
Welcome Remarks Carrie Wang, MD, President-Elect of CABS and 2021 BioPacific Conference Organizing Committee Chair |
|
8:55 AM – 9:00 AM |
State of the Society Yang Tian, PhD, President of CABS |
|
9:00 AM – 9:35 AM |
Keynote 1: Traffic of Cas9-gRNA Between Cultured Human Cells Mediated by Cell-Cell Contact Randy Schekman, PhD, Professor, Department of Molecular and Cell Biology, UC Berkeley 2013 Nobel Prize for Physiology or Medicine |
|
9:35 AM – 10:00 AM |
CABS K. Fong Award in Life Sciences Fireside Chat, Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures LLC Awardees: John O. Link, PhD, Former VP, Gilead Sciences, Inc (Retired) Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences |
|
10:00 AM-10:25 AM |
K. Fong Award Speech: Reshaping Biotech Landscape in China Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences Co. |
|
10:25 AM – 10:50 AM |
K. Fong Award Speech: Lenacapavir: A Twice-Yearly Dosed First-in-Class HIV Capsid Inhibitor John O. Link, PhD, Former VP, Gilead Sciences, Inc (Retired) |
|
10:50 AM – 11:20 AM |
Cancer Immunotherapy Trends and Highlights in the Post-Checkpoint Inhibitor Approval Era Gary Starling, PhD, CSO, Xyphos Biosciences, Astellas Pharma Inc. |
|
11:20 AM – 12:00 PM |
Panel Discussion 1: IP Considerations and Investment Trends for Life Sciences Session will cover intellectual property considerations for life science transactions, investment stories of new technologies, and discussions on a new company structure. Moderator: Janet Xiao, JD, PhD, Partner, Head of China Life Sciences, Morrison & Foerster LLP Panelists: Chuck Comey, Partner, Morrison & Foerster LLP Sean Cao, MBA, PhD, Managing Director, CBC Group Neil Desai, PhD, Founder & CEO, Aadi Bioscience, Inc |
|
12:00 PM – 12:30 PM |
Breakout Room Presentations Room 0: How to Choose Key Reagents for CAR-T Cell Therapy Development Teng Peng, PhD, Technique Application Manager, ACROBiosystems
Room 1: Effective Use of Science in the FDA Regulatory Process Bethany Hills, Partner, Morrison & Foerster LLP Keunbong (KB) Do, JD, PhD, Associate, Morrison & Foerster LLP
Room 2. Precise and Efficient Non-viral CRISPR Gene Editing Solutions Lumeng Ye, PhD, Sr. Scientist, GenScript USA Inc.
Room 3: Humanized Models for Improved Preclinical Discovery and Assessment of Novel Immunotherapies Jenna Frame, PhD, Manager, Scientific Communications & Marketing, Biocytogen Boston Corp.
Room 4: Atomic-resolution cryoEM and Its Impact on SBDD Larry Jin, PhD, COO, Wuxi Biortus Biosciences Co., Ltd. What’s Ahead for the Biotech Industry: Another Wave or Low Tide? Michael Zhao, Co-founder, Q Bay (Boston)
Room 5: Clinical Study in the US and China Charles Li, MBA, MS, VP, Business Development, CR Medicon, a Pharmaron Company Next-Generation DMSO-Free & Serum-Free Cryopreservation for Cell Therapy Manufacturing and Processing Xiaoxi Wei, PhD, Co-founder & CEO, X-Therma Inc. User Affiliate at Lawrence Berkeley National Laboratory
Room 6: Future of Targeted Therapies in Lung Cancer Sanjeev Redkar, MBA, PhD, President and Co-Founder, Apollomics Inc.
Room 7. Opportunities and Challenges in the Development of an Innovative Clinical Research Platform Sophia Kan, Director of Marketing Strategy, GoBroad Healthcare Group Alex J. Zhang, PhD, Chief Scientific Advisor, Hanhai International Inc. |
|
Afternoon Session |
|
|
12:30 PM – 1:05 PM |
Keynote 2: Towards Universal Druggability Greg Verdine, PhD, Professor, Chemical Biology, Harvard University |
|
1:05 PM – 1:35 PM |
How We Use Stem Cells & Genomics for Guiding Precision Medicine Joseph C. Wu, MD, PhD, Director of Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University |
|
1:35 PM – 2:05 PM |
Designing Better Molecules Faster and with Less Expense: Illustrations of the Transformative Impact of Physics-Based Modeling Combined with Machine Learning Matt Repasky, PhD, SVP, Life Sciences Products, Schrödinger Inc. |
|
2:05 PM – 2:35 PM |
The COVID-19 Pandemic: A Status Report Arthur Reingold, MD, Professor and Head of the Division of Epidemiology at the School of Public Health, UC Berkeley |
|
2:35 PM –3:15PM |
Panel Discussion 2: Strategic Partnerships & Financing Trends for the Biotech Industry Moderator: Cheni Kwok, CLP, PhD, Managing Partner & Founder, Linear Dreams LLC Panelists: Edward Harrington, MBA, CFO, Genentech Guo-Liang Yu, PhD, CEO, Apollomics Inc. Dewan Zeng, MBA, PhD, Head of Search and Evaluation, Business Development, BeiGene, Ltd. Cariad Chester, Partner, TCG Crossover “TCG X” |
|
3:15 PM – 3:45 PM |
FDA Experience and Regulatory Considerations on Companion Diagnostics and Cancer Early Detection Test Sharon Liang, MD, RAC, PhD, VP, Regulatory Affairs and Quality Affairs, Burning Rock Dx, LLC |
|
3:45 PM – 4:00 PM |
A World-Class Healthcare Technology Innovation Platform at Hong Kong Science Park Carrie Ling, PhD, Assistant Director of Business Development (InnoHK), Hong Kong Science and Technology Parks Corporation (HKSTP) |
|
4:00 PM – 4:05 PM |
Conference Adjourned |
|
4:05 PM – 4:30 PM |
Breakout Room Networking |
